Document Detail


Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder.
MedLine Citation:
PMID:  2070206     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Following 2 pilot studies which showed 57 and 61% response rates to intravenous cisplatin for transitional cell carcinoma of the bladder prior to definitive treatment, the West Midlands Urological Research Group (WMURG) and the Australian Bladder Cancer Study Group (ABCSG) independently began randomised trials to test the survival benefit of neo-adjuvant intravenous cisplatin prior to radiotherapy in T2-T4 M0 transitional cell carcinoma of the bladder. Both trials failed to recruit their target numbers of 250 patients in the West Midlands and 320 in Australia. Since they had similar treatment protocols and eligibility criteria, they were combined in an overview analysis, achieving a total number of 255 patients. Each treatment group was compared with its own control group and the differences were pooled to give an overall result. There was no difference in survival between treated and control patients. The odds ratio was 1.13 with the control groups faring marginally better than the chemotherapy groups. Even with 255 patients the 95% confidence interval of the odds ratio was wide (0.80-1.57). Although there is no clear evidence of a clinically worthwhile benefit from neo-adjuvant cisplatin, this approach must be tested in a larger study using combination treatments with greater activity in metastatic disease.
Authors:
D M Wallace; D Raghavan; K A Kelly; T F Sandeman; I G Conn; N Teriana; J Dunn; J Boulas; T Latief
Related Documents :
3429166 - Indication of radical cystectomy in patients with carcinoma of the bladder.
1509286 - Chemoradiotherapy in locally advanced bladder carcinoma.
18410436 - Urinary fibronectin as a predictor of a residual tumour load after transurethral resect...
465986 - A trial of prophylactic radiotherapy for non-infiltrating bladder tumours.
9135896 - Tracheostomy and radiotherapy in the management of laryngeal carcinoma causing airway o...
15841636 - Implications of popliteal lymph node detected by sentinel lymph node biopsy.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of urology     Volume:  67     ISSN:  0007-1331     ISO Abbreviation:  Br J Urol     Publication Date:  1991 Jun 
Date Detail:
Created Date:  1991-08-20     Completed Date:  1991-08-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  15740090R     Medline TA:  Br J Urol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  608-15     Citation Subset:  IM    
Affiliation:
Department of Urology, Queen Elizabeth Hospital, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Australia
Carcinoma, Transitional Cell / drug therapy*,  radiotherapy
Cisplatin / administration & dosage,  adverse effects,  therapeutic use*
Combined Modality Therapy
England
Female
Humans
Infusions, Intravenous
Male
Prognosis
Urinary Bladder Neoplasms / drug therapy*,  radiotherapy
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cisplatin combination chemotherapy for elderly patients with urothelial tumours.
Next Document:  Comparison of transrectal ultrasound and magnetic resonance imaging in the staging of prostate cance...